N-aroyl cyclic amines

1. A compound of formula (I):

wherein:

Y represents a group (CH 2 ) n , wherein n represents 1;

m represents 1, 2, or 3;

p represents 0 or 1;

X is NR, wherein R is H or (C 1-4 )alkyl;

Ar 1 is optionally substituted pyrimidinyl;

Ar 2 represents optionally substituted quinolinyl or isoquinolinyl

wherein said optionally substituted Ar 1 and Ar 2 , is optionally substituted by halogen, hydroxy, oxo, cyano, nitro, (C 1-4 )alkyl, (C 1-4 )alkoxy, hydroxy(C 1-4 )alkyl, hydroxy(C 1-4 )alkoxy, halo(C 1-4 )alkyl, halo(C 1-4 )alkoxy, aryl(C 1-4 )alkoxy, (C 1-4 )alkylthio, hydroxy(C 1-4 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, (C 3-6 )cycloalkyl(C 1-4 )alkoxy, (C 1-4 )alkanoyl, (C 1-4 )alkoxycarbonyl, (C 1-4 )allylsulfonyl, (C 1-4 )alkylsulfonyloxy, (C 1-4 )alkylsulfonyl(C 1-4 )alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl(C 1-4 )alkyl, (C 1-4 )alkylsulfonamido, (C 1-4 )alkylamido, (C 1-4 )alkylsulfonamido(C 1-4 )alkyl, (C 1-4 )alkylamido(C 1-4 )alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido(C 1-4 )alkyl, arylcarboxamido(C 1-4 )alkyl, aroyl, aroyl(C 1-4 )alkyl, aryl(C 1-4 )alkanoyl, (C 1-4 )acyl, aryl, aryl(C 1-4 )alkyl, (C 1-4 )alkylamino(C 1-4 )alkyl, R a R b N—, R a OCO(CH 2 ) r , R a CON(R a )(CH 2 ) r , R a R b NCO(CH 2 ) r , R a R b NSO 2 (CH 2 ) r or R a SO 2 NR b (CH 2 ) r , wherein r represents zero or an integer from 1 to 4, or R a R b N(CH 2 )n- or R a R b N(CH 2 )nO—, wherein n represents an integer from 1 to 4, wherein each of R a and R b independently represents a hydrogen atom or a (C 1-4 )alkyl group or R a R b forms part of a (C 3-6 )azacycloalkane or (C 3-6 )(2-oxo)azacycloalkane ring, or R a R b N(CH 2 )n- or R a R b N(CH 2 )nO, where R a with at least one CH 2 of the (CH 2 )n portion of the group form a (C 3-6 )azacycloalkane and R b represents hydrogen, a (C 1-4 )alkyl group or with the nitrogen to which it is attached forms a second (C 3-6 )azacycloalkane fused to the first (C 3-6 )azacycloalkane;

or a pharmaceutically acceptable salt thereof.

2. The compound or salt according to claim 1 , having formula (Ia):

wherein:

Y represents a group (CH 2 ) n , wherein n represents 1;

Ar 1 is optionally substituted pyrimidinyl;

Ar 2 represents optionally substituted quinolinyl or isoquinolinyl

wherein said optionally substituted Ar 1 and Ar 2 , is optionally substituted by halogen, hydroxy, oxo, cyano, nitro, (C 1-4 )alkyl, (C 1-4 )alkoxy, hydroxy(C 1-4 )alkyl, hydroxy(C 1-4 )alkoxy, halo(C 1-4 )alkyl, halo(C 1-4 ) alkoxy, aryl(C 1-4 )alkoxy, (C 1-4 )alkylthio, hydroxy(C 1-4 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, (C 3-6 )cycloalkyl(C 1-4 )alkoxy, (C 1-4 )alkanoyl, (C 1-4 )alkoxycarbonyl, (C 1-4 )alkylsulfonyl, (C 1-4 )alkylsulfonyloxy, (C 1-4 )alkylsulfonyl(C 1-4 )alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl(C 1-4 )alkyl, (C 1-4 )alkylsulfonamido, (C 1-4 )alkylamido, (C 1-4 )alkylsulfonamido(C 1-4 )alkyl, (C 1-4 )alkylamido(C 1-4 )alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido(C 1-4 )alkyl, arylcarboxamido(C 1-4 )alkyl, aroyl, aroyl(C 1-4 )alkyl, aryl(C 1-4 )alkanoyl, (C 1-4 )acyl, aryl, aryl(C 1-4 )alkyl, (C 1-4 )alkylamino(C 1-4 )alkyl, R a R b N—, R a OCO(CH 2 ) r , R a CON(R a )(CH 2 ) r , R a R b NCO(CH 2 ) r , R a R b NSO 2 (CH 2 ), or R a SO 2 NR b (CH 2 ) r , wherein r represents zero or an integer from 1 to 4, or R a R b N(CH 2 )n- or R a R b N(CH 2 )nO—, wherein n represents an integer from 1 to 4, wherein each of R a and R b independently represents a hydrogen atom or a (C 1-4 )alkyl group or R a R b forms part of a (C 3-6 )azacycloalkane or (C 3-6 )(2-oxo)azacycloalkane ring , or R a R b N(CH 2 )n- or R a R b N(CH 2 )nO, where R a with at least one CH 2 of the (CH 2 )n portion of the group form a (C 3-6 )azacycloalkane and R b represents hydrogen, a (C 1-4 )alkyl group or with the nitrogen to which it is attached forms a second (C 3-6 )azacycloalkane fused to the first (C 3-6 )azacycloalkane.

3. The compound or salt according to claim 1 , wherein Ar 2 represents optionally substituted quinolinyl.

4. The compound or salt according to claim 1 , wherein Ar 2 represents optionally substituted quinolinyl.

5. The compound or salt according to claim 1 , wherein Ar 2 represents optionally substituted isoquinolinyl.

6. The compound or salt according to claim 2 , wherein Ar 2 represents optionally substituted isoquinolinyl.

7. A compound selected from:

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-quinolin-2-yl-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-quinolin-8-yl-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-quinolin-4-yl-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(4-ethyl-quinolin-8-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-isoquinolin-1-yl-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(2-methyl-quinolin-5-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(3-methyl-quinolin-4-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(7-chloro-3-methyl-quinolin-8-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-[2,4-dimethyl-quinolin-8-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(2-phenyl-quinolin-4-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(2-methyl-quinolin-4-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(6-bromo-quinolin-4-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(2-methyl-quinolin-8-yl)-methanone,

1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-(8-bromo-quinolin-4-yl)-methanone,

1-((S)-2-{[(5-Bromo-pyrimidin-2-yl)-methyl-amino]-methyl}-piperidin-1-yl)-1-isoquinolin-1-yl-methanone,

1-((S)-2-{[(5-Bromo-pyrimidin-2-yl)-methyl-amino]-methyl}-piperidin-1-yl)-1-(3-methyl-quinolin-4-yl)-methanone,

1-((S)-2-{[(5-Bromo-pyrimidin-2-yl)-methyl-amino]-methyl}-piperidin-1-yl)-1-(2-methyl-quinolin-5-yl)-methanone,

and a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a therapeutically effective amount of the compound or salt according to claim 1 , and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound or salt according to claim 7 , and a pharmaceutically acceptable carrier.

10. A method of treating a disease or disorder where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein said disease or disorder is selected from obesity and obesity associated with Type II diabetes.

11. A method of treating a disease or disorder where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of the compound according to claim 7 , or a pharmaceutically acceptable salt thereof, wherein said disease or disorder is selected from obesity and obesity associated with Type II diabetes.

12. A method of treating insomnia which comprises administering to a subject in need thereof an effective amount of the compound or salt according to claim 1 , or a pharmaceutically acceptable salt thereof.

13. A method of treating insomnia which comprises administering to a subject in need thereof an effective amount of the compound or salt according to claim 7 , or a pharmaceutically acceptable salt thereof.